GLPwatch
Adlyxin for Cardiovascular risk reduction
lixisenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCAdlyxin (lixisenatide) is not FDA-approved for reducing cardiovascular risk. Research includes studies on its effects in patients with type 2 diabetes and acute coronary syndrome, such as the ELIXA trial, but these findings are investigational.
AI summary of the sources below.
| Drug | Adlyxin (lixisenatide) |
|---|---|
| Condition | Cardiovascular risk reduction |
| Approval status | Investigational / off-label |
| Research papers | 7 |
Adlyxin is not FDA-approved for cardiovascular risk reduction; the research below reflects investigational or off-label study only.
Research on lixisenatide for cardiovascular risk reduction (7)
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
- The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.
- Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.
- Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.
- Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The ELIXA trial.
- Ameliorative effect of lixisenatide on diabetic cardiovascular damage and its enhancement via ticagrelor co-administration in rats: possible role of eNOS and NrF₂ /HO-1 signaling.